Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.02 USD | +0.67% | +7.47% | -5.03% |
Mar. 07 | Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 07 | Transcript : Lumos Pharma, Inc., 2023 Earnings Call, Mar 07, 2024 |
Financials (USD)
Sales 2024 * | 8.81M | Sales 2025 * | 8.64M | Capitalization | 24.51M |
---|---|---|---|---|---|
Net income 2024 * | -35M | Net income 2025 * | -39M | EV / Sales 2024 * | 2.78 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.84 x |
P/E ratio 2024 * |
-1.07
x | P/E ratio 2025 * |
-1.51
x | Employees | 33 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 64.98% |
Latest transcript on Lumos Pharma, Inc.
1 day | +0.67% | ||
1 week | +7.47% | ||
Current month | +7.47% | ||
1 month | +10.22% | ||
3 months | -0.98% | ||
6 months | -17.03% | ||
Current year | -5.03% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Hawkins
CEO | Chief Executive Officer | 75 | 10-08-31 |
Lori Lawley
DFI | Director of Finance/CFO | 40 | 20-02-29 |
John McKew
PSD | President | 59 | 15-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lota Zoth
BRD | Director/Board Member | 64 | 12-10-31 |
Richard Hawkins
CEO | Chief Executive Officer | 75 | 10-08-31 |
Kevin Lalande
BRD | Director/Board Member | 51 | 13-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-07 | 3.02 | +0.67% | 26,477 |
24-05-06 | 3 | +1.35% | 43,425 |
24-05-03 | 2.96 | -2.63% | 69,636 |
24-05-02 | 3.04 | +0.66% | 128,322 |
24-05-01 | 3.02 | +7.47% | 278,322 |
Delayed Quote Nasdaq, May 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.03% | 24.35M | |
+21.74% | 46.81B | |
-0.97% | 41.37B | |
+47.07% | 41.29B | |
-3.52% | 28.87B | |
+11.12% | 26.06B | |
-19.37% | 19.13B | |
+31.18% | 12.39B | |
-0.04% | 12.08B | |
+0.39% | 11.96B |
- Stock Market
- Equities
- LUMO Stock